Integra LifeSciences Holdings Corporation
Integra LifeSciences Holdings Corporation (IART) Stock Competitors & Peer Comparison
See (IART) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Devices Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| IART | $12.37 | -3.81% | 961.3M | -32.55 | -$0.38 | N/A |
| ABT | $128.55 | +0.42% | 223.7B | 16.13 | $7.97 | +1.81% |
| BSX-PA | $122.18 | +2.37% | 175.4B | 230.53 | $0.53 | N/A |
| BSX | $106.76 | +0.27% | 157.9B | 63.54 | $1.68 | N/A |
| SYK | $400.41 | -0.04% | 153.1B | 54.06 | $7.41 | +0.83% |
| MDT | $91.64 | -0.87% | 117.5B | 25.40 | $3.61 | +3.07% |
| EW | $81.16 | +0.86% | 47.6B | 33.97 | $2.39 | N/A |
| DXCM | $89.06 | -0.32% | 34.9B | 66.96 | $1.33 | N/A |
| PHG | $26.81 | -4.32% | 24.8B | 141.05 | $0.19 | +3.30% |
| STE | $229.27 | +0.39% | 22.6B | 37.24 | $6.16 | +1.00% |
Stock Comparison
IART vs ABT Comparison July 2025
IART plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IART stands at 961.3M. In comparison, ABT has a market cap of 223.7B. Regarding current trading prices, IART is priced at $12.37, while ABT trades at $128.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IART currently has a P/E ratio of -32.55, whereas ABT's P/E ratio is 16.13. In terms of profitability, IART's ROE is -0.03%, compared to ABT's ROE of +0.32%. Regarding short-term risk, IART is more volatile compared to ABT. This indicates potentially higher risk in terms of short-term price fluctuations for IART.Check ABT's competition here
IART vs BSX-PA Comparison July 2025
IART plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IART stands at 961.3M. In comparison, BSX-PA has a market cap of 175.4B. Regarding current trading prices, IART is priced at $12.37, while BSX-PA trades at $122.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IART currently has a P/E ratio of -32.55, whereas BSX-PA's P/E ratio is 230.53. In terms of profitability, IART's ROE is -0.03%, compared to BSX-PA's ROE of +0.12%. Regarding short-term risk, IART is more volatile compared to BSX-PA. This indicates potentially higher risk in terms of short-term price fluctuations for IART.Check BSX-PA's competition here
IART vs BSX Comparison July 2025
IART plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IART stands at 961.3M. In comparison, BSX has a market cap of 157.9B. Regarding current trading prices, IART is priced at $12.37, while BSX trades at $106.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IART currently has a P/E ratio of -32.55, whereas BSX's P/E ratio is 63.54. In terms of profitability, IART's ROE is -0.03%, compared to BSX's ROE of +0.12%. Regarding short-term risk, IART is more volatile compared to BSX. This indicates potentially higher risk in terms of short-term price fluctuations for IART.Check BSX's competition here
IART vs SYK Comparison July 2025
IART plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IART stands at 961.3M. In comparison, SYK has a market cap of 153.1B. Regarding current trading prices, IART is priced at $12.37, while SYK trades at $400.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IART currently has a P/E ratio of -32.55, whereas SYK's P/E ratio is 54.06. In terms of profitability, IART's ROE is -0.03%, compared to SYK's ROE of +0.11%. Regarding short-term risk, IART is more volatile compared to SYK. This indicates potentially higher risk in terms of short-term price fluctuations for IART.Check SYK's competition here
IART vs MDT Comparison July 2025
IART plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IART stands at 961.3M. In comparison, MDT has a market cap of 117.5B. Regarding current trading prices, IART is priced at $12.37, while MDT trades at $91.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IART currently has a P/E ratio of -32.55, whereas MDT's P/E ratio is 25.40. In terms of profitability, IART's ROE is -0.03%, compared to MDT's ROE of +0.10%. Regarding short-term risk, IART is more volatile compared to MDT. This indicates potentially higher risk in terms of short-term price fluctuations for IART.Check MDT's competition here
IART vs EW Comparison July 2025
IART plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IART stands at 961.3M. In comparison, EW has a market cap of 47.6B. Regarding current trading prices, IART is priced at $12.37, while EW trades at $81.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IART currently has a P/E ratio of -32.55, whereas EW's P/E ratio is 33.97. In terms of profitability, IART's ROE is -0.03%, compared to EW's ROE of +0.45%. Regarding short-term risk, IART is more volatile compared to EW. This indicates potentially higher risk in terms of short-term price fluctuations for IART.Check EW's competition here
IART vs DXCM Comparison July 2025
IART plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IART stands at 961.3M. In comparison, DXCM has a market cap of 34.9B. Regarding current trading prices, IART is priced at $12.37, while DXCM trades at $89.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IART currently has a P/E ratio of -32.55, whereas DXCM's P/E ratio is 66.96. In terms of profitability, IART's ROE is -0.03%, compared to DXCM's ROE of +0.24%. Regarding short-term risk, IART is more volatile compared to DXCM. This indicates potentially higher risk in terms of short-term price fluctuations for IART.Check DXCM's competition here
IART vs PHG Comparison July 2025
IART plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IART stands at 961.3M. In comparison, PHG has a market cap of 24.8B. Regarding current trading prices, IART is priced at $12.37, while PHG trades at $26.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IART currently has a P/E ratio of -32.55, whereas PHG's P/E ratio is 141.05. In terms of profitability, IART's ROE is -0.03%, compared to PHG's ROE of +0.03%. Regarding short-term risk, IART is more volatile compared to PHG. This indicates potentially higher risk in terms of short-term price fluctuations for IART.Check PHG's competition here
IART vs STE Comparison July 2025
IART plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IART stands at 961.3M. In comparison, STE has a market cap of 22.6B. Regarding current trading prices, IART is priced at $12.37, while STE trades at $229.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IART currently has a P/E ratio of -32.55, whereas STE's P/E ratio is 37.24. In terms of profitability, IART's ROE is -0.03%, compared to STE's ROE of +0.09%. Regarding short-term risk, IART is more volatile compared to STE. This indicates potentially higher risk in terms of short-term price fluctuations for IART.Check STE's competition here
IART vs PODD Comparison July 2025
IART plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IART stands at 961.3M. In comparison, PODD has a market cap of 21B. Regarding current trading prices, IART is priced at $12.37, while PODD trades at $298.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IART currently has a P/E ratio of -32.55, whereas PODD's P/E ratio is 53.84. In terms of profitability, IART's ROE is -0.03%, compared to PODD's ROE of +0.35%. Regarding short-term risk, IART is more volatile compared to PODD. This indicates potentially higher risk in terms of short-term price fluctuations for IART.Check PODD's competition here
IART vs ZBH Comparison July 2025
IART plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IART stands at 961.3M. In comparison, ZBH has a market cap of 18.5B. Regarding current trading prices, IART is priced at $12.37, while ZBH trades at $93.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IART currently has a P/E ratio of -32.55, whereas ZBH's P/E ratio is 20.75. In terms of profitability, IART's ROE is -0.03%, compared to ZBH's ROE of +0.07%. Regarding short-term risk, IART is more volatile compared to ZBH. This indicates potentially higher risk in terms of short-term price fluctuations for IART.Check ZBH's competition here
IART vs ABMD Comparison July 2025
IART plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IART stands at 961.3M. In comparison, ABMD has a market cap of 17.2B. Regarding current trading prices, IART is priced at $12.37, while ABMD trades at $381.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IART currently has a P/E ratio of -32.55, whereas ABMD's P/E ratio is 65.36. In terms of profitability, IART's ROE is -0.03%, compared to ABMD's ROE of +0.10%. Regarding short-term risk, IART is more volatile compared to ABMD. This indicates potentially higher risk in terms of short-term price fluctuations for IART.Check ABMD's competition here
IART vs ALGN Comparison July 2025
IART plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IART stands at 961.3M. In comparison, ALGN has a market cap of 14.8B. Regarding current trading prices, IART is priced at $12.37, while ALGN trades at $203.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IART currently has a P/E ratio of -32.55, whereas ALGN's P/E ratio is 37.01. In terms of profitability, IART's ROE is -0.03%, compared to ALGN's ROE of +0.11%. Regarding short-term risk, IART is more volatile compared to ALGN. This indicates potentially higher risk in terms of short-term price fluctuations for IART.Check ALGN's competition here
IART vs SNN Comparison July 2025
IART plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IART stands at 961.3M. In comparison, SNN has a market cap of 13.5B. Regarding current trading prices, IART is priced at $12.37, while SNN trades at $30.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IART currently has a P/E ratio of -32.55, whereas SNN's P/E ratio is 32.90. In terms of profitability, IART's ROE is -0.03%, compared to SNN's ROE of +0.08%. Regarding short-term risk, IART is more volatile compared to SNN. This indicates potentially higher risk in terms of short-term price fluctuations for IART.Check SNN's competition here
IART vs SWAV Comparison July 2025
IART plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IART stands at 961.3M. In comparison, SWAV has a market cap of 12.6B. Regarding current trading prices, IART is priced at $12.37, while SWAV trades at $334.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IART currently has a P/E ratio of -32.55, whereas SWAV's P/E ratio is 78.76. In terms of profitability, IART's ROE is -0.03%, compared to SWAV's ROE of +0.14%. Regarding short-term risk, IART is more volatile compared to SWAV. This indicates potentially higher risk in terms of short-term price fluctuations for IART.Check SWAV's competition here
IART vs PEN Comparison July 2025
IART plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IART stands at 961.3M. In comparison, PEN has a market cap of 9.8B. Regarding current trading prices, IART is priced at $12.37, while PEN trades at $254.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IART currently has a P/E ratio of -32.55, whereas PEN's P/E ratio is 233.17. In terms of profitability, IART's ROE is -0.03%, compared to PEN's ROE of +0.12%. Regarding short-term risk, IART is less volatile compared to PEN. This indicates potentially lower risk in terms of short-term price fluctuations for IART.Check PEN's competition here
IART vs GMED Comparison July 2025
IART plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IART stands at 961.3M. In comparison, GMED has a market cap of 7.2B. Regarding current trading prices, IART is priced at $12.37, while GMED trades at $53.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IART currently has a P/E ratio of -32.55, whereas GMED's P/E ratio is 39.89. In terms of profitability, IART's ROE is -0.03%, compared to GMED's ROE of +0.05%. Regarding short-term risk, IART is more volatile compared to GMED. This indicates potentially higher risk in terms of short-term price fluctuations for IART.Check GMED's competition here
IART vs BIO-B Comparison July 2025
IART plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IART stands at 961.3M. In comparison, BIO-B has a market cap of 6.9B. Regarding current trading prices, IART is priced at $12.37, while BIO-B trades at $247.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IART currently has a P/E ratio of -32.55, whereas BIO-B's P/E ratio is -3.23. In terms of profitability, IART's ROE is -0.03%, compared to BIO-B's ROE of -0.32%. Regarding short-term risk, IART is more volatile compared to BIO-B. This indicates potentially higher risk in terms of short-term price fluctuations for IART.Check BIO-B's competition here
IART vs BIO Comparison July 2025
IART plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IART stands at 961.3M. In comparison, BIO has a market cap of 6.8B. Regarding current trading prices, IART is priced at $12.37, while BIO trades at $250.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IART currently has a P/E ratio of -32.55, whereas BIO's P/E ratio is -3.27. In terms of profitability, IART's ROE is -0.03%, compared to BIO's ROE of -0.32%. Regarding short-term risk, IART is more volatile compared to BIO. This indicates potentially higher risk in terms of short-term price fluctuations for IART.Check BIO's competition here
IART vs BRKR Comparison July 2025
IART plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IART stands at 961.3M. In comparison, BRKR has a market cap of 6.2B. Regarding current trading prices, IART is priced at $12.37, while BRKR trades at $40.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IART currently has a P/E ratio of -32.55, whereas BRKR's P/E ratio is 78.64. In terms of profitability, IART's ROE is -0.03%, compared to BRKR's ROE of +0.04%. Regarding short-term risk, IART is more volatile compared to BRKR. This indicates potentially higher risk in terms of short-term price fluctuations for IART.Check BRKR's competition here
IART vs GKOS Comparison July 2025
IART plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IART stands at 961.3M. In comparison, GKOS has a market cap of 5.4B. Regarding current trading prices, IART is priced at $12.37, while GKOS trades at $94.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IART currently has a P/E ratio of -32.55, whereas GKOS's P/E ratio is -41.43. In terms of profitability, IART's ROE is -0.03%, compared to GKOS's ROE of -0.17%. Regarding short-term risk, IART is more volatile compared to GKOS. This indicates potentially higher risk in terms of short-term price fluctuations for IART.Check GKOS's competition here
IART vs NARI Comparison July 2025
IART plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IART stands at 961.3M. In comparison, NARI has a market cap of 4.7B. Regarding current trading prices, IART is priced at $12.37, while NARI trades at $79.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IART currently has a P/E ratio of -32.55, whereas NARI's P/E ratio is -59.24. In terms of profitability, IART's ROE is -0.03%, compared to NARI's ROE of -0.18%. Regarding short-term risk, IART is more volatile compared to NARI. This indicates potentially higher risk in terms of short-term price fluctuations for IART.Check NARI's competition here
IART vs IRTC Comparison July 2025
IART plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IART stands at 961.3M. In comparison, IRTC has a market cap of 4.5B. Regarding current trading prices, IART is priced at $12.37, while IRTC trades at $140.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IART currently has a P/E ratio of -32.55, whereas IRTC's P/E ratio is -44.75. In terms of profitability, IART's ROE is -0.03%, compared to IRTC's ROE of -1.13%. Regarding short-term risk, IART is more volatile compared to IRTC. This indicates potentially higher risk in terms of short-term price fluctuations for IART.Check IRTC's competition here
IART vs INSP Comparison July 2025
IART plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IART stands at 961.3M. In comparison, INSP has a market cap of 3.9B. Regarding current trading prices, IART is priced at $12.37, while INSP trades at $131.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IART currently has a P/E ratio of -32.55, whereas INSP's P/E ratio is 59.96. In terms of profitability, IART's ROE is -0.03%, compared to INSP's ROE of +0.10%. Regarding short-term risk, IART is more volatile compared to INSP. This indicates potentially higher risk in terms of short-term price fluctuations for IART.Check INSP's competition here
IART vs ITGR Comparison July 2025
IART plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IART stands at 961.3M. In comparison, ITGR has a market cap of 3.8B. Regarding current trading prices, IART is priced at $12.37, while ITGR trades at $108.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IART currently has a P/E ratio of -32.55, whereas ITGR's P/E ratio is 46.51. In terms of profitability, IART's ROE is -0.03%, compared to ITGR's ROE of +0.05%. Regarding short-term risk, IART is more volatile compared to ITGR. This indicates potentially higher risk in terms of short-term price fluctuations for IART.Check ITGR's competition here
IART vs TMDX Comparison July 2025
IART plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IART stands at 961.3M. In comparison, TMDX has a market cap of 3.6B. Regarding current trading prices, IART is priced at $12.37, while TMDX trades at $107.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IART currently has a P/E ratio of -32.55, whereas TMDX's P/E ratio is 75.85. In terms of profitability, IART's ROE is -0.03%, compared to TMDX's ROE of +0.22%. Regarding short-term risk, IART is more volatile compared to TMDX. This indicates potentially higher risk in terms of short-term price fluctuations for IART.Check TMDX's competition here
IART vs AXNX Comparison July 2025
IART plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IART stands at 961.3M. In comparison, AXNX has a market cap of 3.6B. Regarding current trading prices, IART is priced at $12.37, while AXNX trades at $70.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IART currently has a P/E ratio of -32.55, whereas AXNX's P/E ratio is -709.80. In terms of profitability, IART's ROE is -0.03%, compared to AXNX's ROE of -0.01%. Regarding short-term risk, IART is more volatile compared to AXNX. This indicates potentially higher risk in terms of short-term price fluctuations for IART.Check AXNX's competition here
IART vs PRCT Comparison July 2025
IART plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IART stands at 961.3M. In comparison, PRCT has a market cap of 2.8B. Regarding current trading prices, IART is priced at $12.37, while PRCT trades at $51.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IART currently has a P/E ratio of -32.55, whereas PRCT's P/E ratio is -30.38. In terms of profitability, IART's ROE is -0.03%, compared to PRCT's ROE of -0.28%. Regarding short-term risk, IART is less volatile compared to PRCT. This indicates potentially lower risk in terms of short-term price fluctuations for IART.Check PRCT's competition here
IART vs LIVN Comparison July 2025
IART plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IART stands at 961.3M. In comparison, LIVN has a market cap of 2.4B. Regarding current trading prices, IART is priced at $12.37, while LIVN trades at $44.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IART currently has a P/E ratio of -32.55, whereas LIVN's P/E ratio is -10.81. In terms of profitability, IART's ROE is -0.03%, compared to LIVN's ROE of -0.18%. Regarding short-term risk, IART is more volatile compared to LIVN. This indicates potentially higher risk in terms of short-term price fluctuations for IART.Check LIVN's competition here
IART vs NUVA Comparison July 2025
IART plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IART stands at 961.3M. In comparison, NUVA has a market cap of 2.1B. Regarding current trading prices, IART is priced at $12.37, while NUVA trades at $39.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IART currently has a P/E ratio of -32.55, whereas NUVA's P/E ratio is 75.00. In terms of profitability, IART's ROE is -0.03%, compared to NUVA's ROE of +0.05%. Regarding short-term risk, IART is more volatile compared to NUVA. This indicates potentially higher risk in terms of short-term price fluctuations for IART.Check NUVA's competition here
IART vs UFPT Comparison July 2025
IART plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IART stands at 961.3M. In comparison, UFPT has a market cap of 1.8B. Regarding current trading prices, IART is priced at $12.37, while UFPT trades at $232.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IART currently has a P/E ratio of -32.55, whereas UFPT's P/E ratio is 28.51. In terms of profitability, IART's ROE is -0.03%, compared to UFPT's ROE of +0.19%. Regarding short-term risk, IART is less volatile compared to UFPT. This indicates potentially lower risk in terms of short-term price fluctuations for IART.Check UFPT's competition here
IART vs ATEC Comparison July 2025
IART plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IART stands at 961.3M. In comparison, ATEC has a market cap of 1.6B. Regarding current trading prices, IART is priced at $12.37, while ATEC trades at $10.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IART currently has a P/E ratio of -32.55, whereas ATEC's P/E ratio is -9.41. In terms of profitability, IART's ROE is -0.03%, compared to ATEC's ROE of -2.58%. Regarding short-term risk, IART is more volatile compared to ATEC. This indicates potentially higher risk in terms of short-term price fluctuations for IART.Check ATEC's competition here
IART vs CNMD Comparison July 2025
IART plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IART stands at 961.3M. In comparison, CNMD has a market cap of 1.6B. Regarding current trading prices, IART is priced at $12.37, while CNMD trades at $50.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IART currently has a P/E ratio of -32.55, whereas CNMD's P/E ratio is 13.16. In terms of profitability, IART's ROE is -0.03%, compared to CNMD's ROE of +0.13%. Regarding short-term risk, IART is more volatile compared to CNMD. This indicates potentially higher risk in terms of short-term price fluctuations for IART.Check CNMD's competition here
IART vs SSII Comparison July 2025
IART plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IART stands at 961.3M. In comparison, SSII has a market cap of 1.4B. Regarding current trading prices, IART is priced at $12.37, while SSII trades at $7.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IART currently has a P/E ratio of -32.55, whereas SSII's P/E ratio is -88.12. In terms of profitability, IART's ROE is -0.03%, compared to SSII's ROE of -1.05%. Regarding short-term risk, IART is less volatile compared to SSII. This indicates potentially lower risk in terms of short-term price fluctuations for IART.Check SSII's competition here
IART vs AORT Comparison July 2025
IART plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IART stands at 961.3M. In comparison, AORT has a market cap of 1.3B. Regarding current trading prices, IART is priced at $12.37, while AORT trades at $31.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IART currently has a P/E ratio of -32.55, whereas AORT's P/E ratio is -61.94. In terms of profitability, IART's ROE is -0.03%, compared to AORT's ROE of -0.07%. Regarding short-term risk, IART is more volatile compared to AORT. This indicates potentially higher risk in terms of short-term price fluctuations for IART.Check AORT's competition here
IART vs HSKA Comparison July 2025
IART plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IART stands at 961.3M. In comparison, HSKA has a market cap of 1.3B. Regarding current trading prices, IART is priced at $12.37, while HSKA trades at $119.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IART currently has a P/E ratio of -32.55, whereas HSKA's P/E ratio is -62.49. In terms of profitability, IART's ROE is -0.03%, compared to HSKA's ROE of -0.04%. Regarding short-term risk, IART is more volatile compared to HSKA. This indicates potentially higher risk in terms of short-term price fluctuations for IART.Check HSKA's competition here
IART vs AHCO Comparison July 2025
IART plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IART stands at 961.3M. In comparison, AHCO has a market cap of 1.2B. Regarding current trading prices, IART is priced at $12.37, while AHCO trades at $9.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IART currently has a P/E ratio of -32.55, whereas AHCO's P/E ratio is 15.74. In terms of profitability, IART's ROE is -0.03%, compared to AHCO's ROE of +0.06%. Regarding short-term risk, IART is more volatile compared to AHCO. This indicates potentially higher risk in terms of short-term price fluctuations for IART.Check AHCO's competition here
IART vs ESTA Comparison July 2025
IART plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IART stands at 961.3M. In comparison, ESTA has a market cap of 1.2B. Regarding current trading prices, IART is priced at $12.37, while ESTA trades at $41.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IART currently has a P/E ratio of -32.55, whereas ESTA's P/E ratio is -13.45. In terms of profitability, IART's ROE is -0.03%, compared to ESTA's ROE of -2.10%. Regarding short-term risk, IART is more volatile compared to ESTA. This indicates potentially higher risk in terms of short-term price fluctuations for IART.Check ESTA's competition here
IART vs SILK Comparison July 2025
IART plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IART stands at 961.3M. In comparison, SILK has a market cap of 1.1B. Regarding current trading prices, IART is priced at $12.37, while SILK trades at $27.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IART currently has a P/E ratio of -32.55, whereas SILK's P/E ratio is -18.96. In terms of profitability, IART's ROE is -0.03%, compared to SILK's ROE of -0.29%. Regarding short-term risk, IART is more volatile compared to SILK. This indicates potentially higher risk in terms of short-term price fluctuations for IART.Check SILK's competition here
IART vs TNDM Comparison July 2025
IART plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IART stands at 961.3M. In comparison, TNDM has a market cap of 1.1B. Regarding current trading prices, IART is priced at $12.37, while TNDM trades at $16.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IART currently has a P/E ratio of -32.55, whereas TNDM's P/E ratio is -5.97. In terms of profitability, IART's ROE is -0.03%, compared to TNDM's ROE of -0.83%. Regarding short-term risk, IART is more volatile compared to TNDM. This indicates potentially higher risk in terms of short-term price fluctuations for IART.Check TNDM's competition here
IART vs FNA Comparison July 2025
IART plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IART stands at 961.3M. In comparison, FNA has a market cap of 1.1B. Regarding current trading prices, IART is priced at $12.37, while FNA trades at $13.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IART currently has a P/E ratio of -32.55, whereas FNA's P/E ratio is -19.83. In terms of profitability, IART's ROE is -0.03%, compared to FNA's ROE of -0.36%. Regarding short-term risk, IART is more volatile compared to FNA. This indicates potentially higher risk in terms of short-term price fluctuations for IART.Check FNA's competition here
IART vs INMD Comparison July 2025
IART plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IART stands at 961.3M. In comparison, INMD has a market cap of 966.9M. Regarding current trading prices, IART is priced at $12.37, while INMD trades at $13.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IART currently has a P/E ratio of -32.55, whereas INMD's P/E ratio is 6.23. In terms of profitability, IART's ROE is -0.03%, compared to INMD's ROE of +0.25%. Regarding short-term risk, IART is more volatile compared to INMD. This indicates potentially higher risk in terms of short-term price fluctuations for IART.Check INMD's competition here
IART vs CSII Comparison July 2025
IART plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IART stands at 961.3M. In comparison, CSII has a market cap of 844M. Regarding current trading prices, IART is priced at $12.37, while CSII trades at $20.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IART currently has a P/E ratio of -32.55, whereas CSII's P/E ratio is -20.83. In terms of profitability, IART's ROE is -0.03%, compared to CSII's ROE of -0.14%. Regarding short-term risk, IART is more volatile compared to CSII. This indicates potentially higher risk in terms of short-term price fluctuations for IART.Check CSII's competition here
IART vs SIBN Comparison July 2025
IART plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IART stands at 961.3M. In comparison, SIBN has a market cap of 758.5M. Regarding current trading prices, IART is priced at $12.37, while SIBN trades at $17.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IART currently has a P/E ratio of -32.55, whereas SIBN's P/E ratio is -28.25. In terms of profitability, IART's ROE is -0.03%, compared to SIBN's ROE of -0.16%. Regarding short-term risk, IART is more volatile compared to SIBN. This indicates potentially higher risk in terms of short-term price fluctuations for IART.Check SIBN's competition here
IART vs IRMD Comparison July 2025
IART plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IART stands at 961.3M. In comparison, IRMD has a market cap of 742.2M. Regarding current trading prices, IART is priced at $12.37, while IRMD trades at $58.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IART currently has a P/E ratio of -32.55, whereas IRMD's P/E ratio is 37.66. In terms of profitability, IART's ROE is -0.03%, compared to IRMD's ROE of +0.23%. Regarding short-term risk, IART is more volatile compared to IRMD. This indicates potentially higher risk in terms of short-term price fluctuations for IART.Check IRMD's competition here
IART vs CRY Comparison July 2025
IART plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IART stands at 961.3M. In comparison, CRY has a market cap of 725.1M. Regarding current trading prices, IART is priced at $12.37, while CRY trades at $17.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IART currently has a P/E ratio of -32.55, whereas CRY's P/E ratio is 425.71. In terms of profitability, IART's ROE is -0.03%, compared to CRY's ROE of -0.07%. Regarding short-term risk, IART is more volatile compared to CRY. This indicates potentially higher risk in terms of short-term price fluctuations for IART.Check CRY's competition here
IART vs SMLR Comparison July 2025
IART plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IART stands at 961.3M. In comparison, SMLR has a market cap of 655.5M. Regarding current trading prices, IART is priced at $12.37, while SMLR trades at $35.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IART currently has a P/E ratio of -32.55, whereas SMLR's P/E ratio is -15.03. In terms of profitability, IART's ROE is -0.03%, compared to SMLR's ROE of -0.21%. Regarding short-term risk, IART is more volatile compared to SMLR. This indicates potentially higher risk in terms of short-term price fluctuations for IART.Check SMLR's competition here
IART vs AXGN Comparison July 2025
IART plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IART stands at 961.3M. In comparison, AXGN has a market cap of 601.2M. Regarding current trading prices, IART is priced at $12.37, while AXGN trades at $13.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IART currently has a P/E ratio of -32.55, whereas AXGN's P/E ratio is -82.50. In terms of profitability, IART's ROE is -0.03%, compared to AXGN's ROE of -0.07%. Regarding short-term risk, IART is less volatile compared to AXGN. This indicates potentially lower risk in terms of short-term price fluctuations for IART.Check AXGN's competition here
IART vs APEN Comparison July 2025
IART plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IART stands at 961.3M. In comparison, APEN has a market cap of 579.7M. Regarding current trading prices, IART is priced at $12.37, while APEN trades at $10.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IART currently has a P/E ratio of -32.55, whereas APEN's P/E ratio is -9.43. In terms of profitability, IART's ROE is -0.03%, compared to APEN's ROE of -0.85%. Regarding short-term risk, IART is more volatile compared to APEN. This indicates potentially higher risk in terms of short-term price fluctuations for IART.Check APEN's competition here
IART vs AVNS Comparison July 2025
IART plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IART stands at 961.3M. In comparison, AVNS has a market cap of 540.1M. Regarding current trading prices, IART is priced at $12.37, while AVNS trades at $11.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IART currently has a P/E ratio of -32.55, whereas AVNS's P/E ratio is -1.41. In terms of profitability, IART's ROE is -0.03%, compared to AVNS's ROE of -0.37%. Regarding short-term risk, IART is more volatile compared to AVNS. This indicates potentially higher risk in terms of short-term price fluctuations for IART.Check AVNS's competition here
IART vs CBLL Comparison July 2025
IART plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IART stands at 961.3M. In comparison, CBLL has a market cap of 539.3M. Regarding current trading prices, IART is priced at $12.37, while CBLL trades at $14.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IART currently has a P/E ratio of -32.55, whereas CBLL's P/E ratio is -12.03. In terms of profitability, IART's ROE is -0.03%, compared to CBLL's ROE of -1.64%. Regarding short-term risk, IART is more volatile compared to CBLL. This indicates potentially higher risk in terms of short-term price fluctuations for IART.Check CBLL's competition here
IART vs KIDS Comparison July 2025
IART plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IART stands at 961.3M. In comparison, KIDS has a market cap of 537M. Regarding current trading prices, IART is priced at $12.37, while KIDS trades at $21.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IART currently has a P/E ratio of -32.55, whereas KIDS's P/E ratio is -12.32. In terms of profitability, IART's ROE is -0.03%, compared to KIDS's ROE of -0.11%. Regarding short-term risk, IART is less volatile compared to KIDS. This indicates potentially lower risk in terms of short-term price fluctuations for IART.Check KIDS's competition here
IART vs SRDX Comparison July 2025
IART plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IART stands at 961.3M. In comparison, SRDX has a market cap of 535.2M. Regarding current trading prices, IART is priced at $12.37, while SRDX trades at $37.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IART currently has a P/E ratio of -32.55, whereas SRDX's P/E ratio is -26.74. In terms of profitability, IART's ROE is -0.03%, compared to SRDX's ROE of -0.17%. Regarding short-term risk, IART is more volatile compared to SRDX. This indicates potentially higher risk in terms of short-term price fluctuations for IART.Check SRDX's competition here
IART vs ZIMV Comparison July 2025
IART plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IART stands at 961.3M. In comparison, ZIMV has a market cap of 532.4M. Regarding current trading prices, IART is priced at $12.37, while ZIMV trades at $18.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IART currently has a P/E ratio of -32.55, whereas ZIMV's P/E ratio is -20.98. In terms of profitability, IART's ROE is -0.03%, compared to ZIMV's ROE of -0.04%. Regarding short-term risk, IART is more volatile compared to ZIMV. This indicates potentially higher risk in terms of short-term price fluctuations for IART.Check ZIMV's competition here
IART vs BFLY-WT Comparison July 2025
IART plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IART stands at 961.3M. In comparison, BFLY-WT has a market cap of 471.4M. Regarding current trading prices, IART is priced at $12.37, while BFLY-WT trades at $0.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IART currently has a P/E ratio of -32.55, whereas BFLY-WT's P/E ratio is N/A. In terms of profitability, IART's ROE is -0.03%, compared to BFLY-WT's ROE of -0.33%. Regarding short-term risk, IART is less volatile compared to BFLY-WT. This indicates potentially lower risk in terms of short-term price fluctuations for IART.Check BFLY-WT's competition here
IART vs CTKB Comparison July 2025
IART plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IART stands at 961.3M. In comparison, CTKB has a market cap of 449.6M. Regarding current trading prices, IART is priced at $12.37, while CTKB trades at $3.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IART currently has a P/E ratio of -32.55, whereas CTKB's P/E ratio is -39.44. In terms of profitability, IART's ROE is -0.03%, compared to CTKB's ROE of -0.03%. Regarding short-term risk, IART is less volatile compared to CTKB. This indicates potentially lower risk in terms of short-term price fluctuations for IART.Check CTKB's competition here
IART vs PACB Comparison July 2025
IART plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IART stands at 961.3M. In comparison, PACB has a market cap of 447.1M. Regarding current trading prices, IART is priced at $12.37, while PACB trades at $1.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IART currently has a P/E ratio of -32.55, whereas PACB's P/E ratio is -0.54. In terms of profitability, IART's ROE is -0.03%, compared to PACB's ROE of -1.70%. Regarding short-term risk, IART is less volatile compared to PACB. This indicates potentially lower risk in terms of short-term price fluctuations for IART.Check PACB's competition here
IART vs BFLY Comparison July 2025
IART plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IART stands at 961.3M. In comparison, BFLY has a market cap of 446.4M. Regarding current trading prices, IART is priced at $12.37, while BFLY trades at $1.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IART currently has a P/E ratio of -32.55, whereas BFLY's P/E ratio is -6.02. In terms of profitability, IART's ROE is -0.03%, compared to BFLY's ROE of -0.33%. Regarding short-term risk, IART is more volatile compared to BFLY. This indicates potentially higher risk in terms of short-term price fluctuations for IART.Check BFLY's competition here
IART vs OFIX Comparison July 2025
IART plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IART stands at 961.3M. In comparison, OFIX has a market cap of 445.1M. Regarding current trading prices, IART is priced at $12.37, while OFIX trades at $11.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IART currently has a P/E ratio of -32.55, whereas OFIX's P/E ratio is -3.07. In terms of profitability, IART's ROE is -0.03%, compared to OFIX's ROE of -0.28%. Regarding short-term risk, IART is more volatile compared to OFIX. This indicates potentially higher risk in terms of short-term price fluctuations for IART.Check OFIX's competition here
IART vs BVS Comparison July 2025
IART plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IART stands at 961.3M. In comparison, BVS has a market cap of 434M. Regarding current trading prices, IART is priced at $12.37, while BVS trades at $6.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IART currently has a P/E ratio of -32.55, whereas BVS's P/E ratio is -13.62. In terms of profitability, IART's ROE is -0.03%, compared to BVS's ROE of -0.21%. Regarding short-term risk, IART is less volatile compared to BVS. This indicates potentially lower risk in terms of short-term price fluctuations for IART.Check BVS's competition here
IART vs SENS Comparison July 2025
IART plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IART stands at 961.3M. In comparison, SENS has a market cap of 367.1M. Regarding current trading prices, IART is priced at $12.37, while SENS trades at $0.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IART currently has a P/E ratio of -32.55, whereas SENS's P/E ratio is -4.42. In terms of profitability, IART's ROE is -0.03%, compared to SENS's ROE of -7.46%. Regarding short-term risk, IART is more volatile compared to SENS. This indicates potentially higher risk in terms of short-term price fluctuations for IART.Check SENS's competition here
IART vs TMCI Comparison July 2025
IART plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IART stands at 961.3M. In comparison, TMCI has a market cap of 348.5M. Regarding current trading prices, IART is priced at $12.37, while TMCI trades at $5.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IART currently has a P/E ratio of -32.55, whereas TMCI's P/E ratio is -6.52. In terms of profitability, IART's ROE is -0.03%, compared to TMCI's ROE of -0.49%. Regarding short-term risk, IART is less volatile compared to TMCI. This indicates potentially lower risk in terms of short-term price fluctuations for IART.Check TMCI's competition here
IART vs RXST Comparison July 2025
IART plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IART stands at 961.3M. In comparison, RXST has a market cap of 324.3M. Regarding current trading prices, IART is priced at $12.37, while RXST trades at $7.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IART currently has a P/E ratio of -32.55, whereas RXST's P/E ratio is -12.09. In terms of profitability, IART's ROE is -0.03%, compared to RXST's ROE of -0.10%. Regarding short-term risk, IART is less volatile compared to RXST. This indicates potentially lower risk in terms of short-term price fluctuations for IART.Check RXST's competition here
IART vs VREX Comparison July 2025
IART plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IART stands at 961.3M. In comparison, VREX has a market cap of 309.2M. Regarding current trading prices, IART is priced at $12.37, while VREX trades at $7.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IART currently has a P/E ratio of -32.55, whereas VREX's P/E ratio is -7.23. In terms of profitability, IART's ROE is -0.03%, compared to VREX's ROE of -0.08%. Regarding short-term risk, IART is less volatile compared to VREX. This indicates potentially lower risk in terms of short-term price fluctuations for IART.Check VREX's competition here
IART vs SNWV Comparison July 2025
IART plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IART stands at 961.3M. In comparison, SNWV has a market cap of 308.4M. Regarding current trading prices, IART is priced at $12.37, while SNWV trades at $35.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IART currently has a P/E ratio of -32.55, whereas SNWV's P/E ratio is -5.78. In terms of profitability, IART's ROE is -0.03%, compared to SNWV's ROE of +1.00%. Regarding short-term risk, IART is less volatile compared to SNWV. This indicates potentially lower risk in terms of short-term price fluctuations for IART.Check SNWV's competition here
IART vs NNOX Comparison July 2025
IART plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IART stands at 961.3M. In comparison, NNOX has a market cap of 305.4M. Regarding current trading prices, IART is priced at $12.37, while NNOX trades at $4.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IART currently has a P/E ratio of -32.55, whereas NNOX's P/E ratio is -5.26. In terms of profitability, IART's ROE is -0.03%, compared to NNOX's ROE of -0.31%. Regarding short-term risk, IART is less volatile compared to NNOX. This indicates potentially lower risk in terms of short-term price fluctuations for IART.Check NNOX's competition here
IART vs CLPT Comparison July 2025
IART plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IART stands at 961.3M. In comparison, CLPT has a market cap of 301.3M. Regarding current trading prices, IART is priced at $12.37, while CLPT trades at $10.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IART currently has a P/E ratio of -32.55, whereas CLPT's P/E ratio is -14.03. In terms of profitability, IART's ROE is -0.03%, compared to CLPT's ROE of -0.78%. Regarding short-term risk, IART is more volatile compared to CLPT. This indicates potentially higher risk in terms of short-term price fluctuations for IART.Check CLPT's competition here
IART vs OM Comparison July 2025
IART plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IART stands at 961.3M. In comparison, OM has a market cap of 299.5M. Regarding current trading prices, IART is priced at $12.37, while OM trades at $16.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IART currently has a P/E ratio of -32.55, whereas OM's P/E ratio is -0.59. In terms of profitability, IART's ROE is -0.03%, compared to OM's ROE of -1.45%. Regarding short-term risk, IART is less volatile compared to OM. This indicates potentially lower risk in terms of short-term price fluctuations for IART.Check OM's competition here
IART vs PTHL Comparison July 2025
IART plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IART stands at 961.3M. In comparison, PTHL has a market cap of 294.1M. Regarding current trading prices, IART is priced at $12.37, while PTHL trades at $1.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IART currently has a P/E ratio of -32.55, whereas PTHL's P/E ratio is -22.00. In terms of profitability, IART's ROE is -0.03%, compared to PTHL's ROE of -0.30%. Regarding short-term risk, IART is less volatile compared to PTHL. This indicates potentially lower risk in terms of short-term price fluctuations for IART.Check PTHL's competition here
IART vs CATX Comparison July 2025
IART plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IART stands at 961.3M. In comparison, CATX has a market cap of 288.7M. Regarding current trading prices, IART is priced at $12.37, while CATX trades at $3.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IART currently has a P/E ratio of -32.55, whereas CATX's P/E ratio is -3.16. In terms of profitability, IART's ROE is -0.03%, compared to CATX's ROE of -0.27%. Regarding short-term risk, IART is less volatile compared to CATX. This indicates potentially lower risk in terms of short-term price fluctuations for IART.Check CATX's competition here
IART vs NPCE Comparison July 2025
IART plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IART stands at 961.3M. In comparison, NPCE has a market cap of 287.3M. Regarding current trading prices, IART is priced at $12.37, while NPCE trades at $8.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IART currently has a P/E ratio of -32.55, whereas NPCE's P/E ratio is -10.68. In terms of profitability, IART's ROE is -0.03%, compared to NPCE's ROE of -1.40%. Regarding short-term risk, IART is more volatile compared to NPCE. This indicates potentially higher risk in terms of short-term price fluctuations for IART.Check NPCE's competition here
IART vs QTRX Comparison July 2025
IART plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IART stands at 961.3M. In comparison, QTRX has a market cap of 284.1M. Regarding current trading prices, IART is priced at $12.37, while QTRX trades at $6.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IART currently has a P/E ratio of -32.55, whereas QTRX's P/E ratio is -4.91. In terms of profitability, IART's ROE is -0.03%, compared to QTRX's ROE of -0.15%. Regarding short-term risk, IART is less volatile compared to QTRX. This indicates potentially lower risk in terms of short-term price fluctuations for IART.Check QTRX's competition here
IART vs CERS Comparison July 2025
IART plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IART stands at 961.3M. In comparison, CERS has a market cap of 250.4M. Regarding current trading prices, IART is priced at $12.37, while CERS trades at $1.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IART currently has a P/E ratio of -32.55, whereas CERS's P/E ratio is -13.10. In terms of profitability, IART's ROE is -0.03%, compared to CERS's ROE of -0.35%. Regarding short-term risk, IART is less volatile compared to CERS. This indicates potentially lower risk in terms of short-term price fluctuations for IART.Check CERS's competition here
IART vs VMD Comparison July 2025
IART plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IART stands at 961.3M. In comparison, VMD has a market cap of 244.3M. Regarding current trading prices, IART is priced at $12.37, while VMD trades at $6.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IART currently has a P/E ratio of -32.55, whereas VMD's P/E ratio is 20.60. In terms of profitability, IART's ROE is -0.03%, compared to VMD's ROE of +0.10%. Regarding short-term risk, IART is more volatile compared to VMD. This indicates potentially higher risk in terms of short-term price fluctuations for IART.Check VMD's competition here
IART vs MASS Comparison July 2025
IART plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IART stands at 961.3M. In comparison, MASS has a market cap of 244.2M. Regarding current trading prices, IART is priced at $12.37, while MASS trades at $6.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IART currently has a P/E ratio of -32.55, whereas MASS's P/E ratio is -3.07. In terms of profitability, IART's ROE is -0.03%, compared to MASS's ROE of -0.13%. Regarding short-term risk, IART is less volatile compared to MASS. This indicates potentially lower risk in terms of short-term price fluctuations for IART.Check MASS's competition here
IART vs TCMD Comparison July 2025
IART plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IART stands at 961.3M. In comparison, TCMD has a market cap of 236M. Regarding current trading prices, IART is priced at $12.37, while TCMD trades at $10.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IART currently has a P/E ratio of -32.55, whereas TCMD's P/E ratio is 15.38. In terms of profitability, IART's ROE is -0.03%, compared to TCMD's ROE of +0.08%. Regarding short-term risk, IART is more volatile compared to TCMD. This indicates potentially higher risk in terms of short-term price fluctuations for IART.Check TCMD's competition here
IART vs MXCT Comparison July 2025
IART plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IART stands at 961.3M. In comparison, MXCT has a market cap of 224.3M. Regarding current trading prices, IART is priced at $12.37, while MXCT trades at $2.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IART currently has a P/E ratio of -32.55, whereas MXCT's P/E ratio is -5.27. In terms of profitability, IART's ROE is -0.03%, compared to MXCT's ROE of -0.20%. Regarding short-term risk, IART is more volatile compared to MXCT. This indicates potentially higher risk in terms of short-term price fluctuations for IART.Check MXCT's competition here
IART vs NVRO Comparison July 2025
IART plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IART stands at 961.3M. In comparison, NVRO has a market cap of 224.1M. Regarding current trading prices, IART is priced at $12.37, while NVRO trades at $5.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IART currently has a P/E ratio of -32.55, whereas NVRO's P/E ratio is -1.91. In terms of profitability, IART's ROE is -0.03%, compared to NVRO's ROE of -0.43%. Regarding short-term risk, IART is more volatile compared to NVRO. This indicates potentially higher risk in terms of short-term price fluctuations for IART.Check NVRO's competition here
IART vs BWAY Comparison July 2025
IART plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IART stands at 961.3M. In comparison, BWAY has a market cap of 222M. Regarding current trading prices, IART is priced at $12.37, while BWAY trades at $11.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IART currently has a P/E ratio of -32.55, whereas BWAY's P/E ratio is 53.41. In terms of profitability, IART's ROE is -0.03%, compared to BWAY's ROE of +0.07%. Regarding short-term risk, IART is more volatile compared to BWAY. This indicates potentially higher risk in terms of short-term price fluctuations for IART.Check BWAY's competition here
IART vs CVRX Comparison July 2025
IART plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IART stands at 961.3M. In comparison, CVRX has a market cap of 215.4M. Regarding current trading prices, IART is priced at $12.37, while CVRX trades at $8.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IART currently has a P/E ratio of -32.55, whereas CVRX's P/E ratio is -3.86. In terms of profitability, IART's ROE is -0.03%, compared to CVRX's ROE of -0.79%. Regarding short-term risk, IART is less volatile compared to CVRX. This indicates potentially lower risk in terms of short-term price fluctuations for IART.Check CVRX's competition here
IART vs EYES Comparison July 2025
IART plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IART stands at 961.3M. In comparison, EYES has a market cap of 210M. Regarding current trading prices, IART is priced at $12.37, while EYES trades at $4.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IART currently has a P/E ratio of -32.55, whereas EYES's P/E ratio is N/A. In terms of profitability, IART's ROE is -0.03%, compared to EYES's ROE of -0.26%. Regarding short-term risk, IART is more volatile compared to EYES. This indicates potentially higher risk in terms of short-term price fluctuations for IART.Check EYES's competition here
IART vs MGRM Comparison July 2025
IART plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IART stands at 961.3M. In comparison, MGRM has a market cap of 202.9M. Regarding current trading prices, IART is priced at $12.37, while MGRM trades at $5.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IART currently has a P/E ratio of -32.55, whereas MGRM's P/E ratio is -11.22. In terms of profitability, IART's ROE is -0.03%, compared to MGRM's ROE of -1.26%. Regarding short-term risk, IART is more volatile compared to MGRM. This indicates potentially higher risk in terms of short-term price fluctuations for IART.Check MGRM's competition here
IART vs SGHT Comparison July 2025
IART plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IART stands at 961.3M. In comparison, SGHT has a market cap of 178.4M. Regarding current trading prices, IART is priced at $12.37, while SGHT trades at $3.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IART currently has a P/E ratio of -32.55, whereas SGHT's P/E ratio is -3.52. In terms of profitability, IART's ROE is -0.03%, compared to SGHT's ROE of -0.55%. Regarding short-term risk, IART is less volatile compared to SGHT. This indicates potentially lower risk in terms of short-term price fluctuations for IART.Check SGHT's competition here
IART vs INGN Comparison July 2025
IART plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IART stands at 961.3M. In comparison, INGN has a market cap of 176.1M. Regarding current trading prices, IART is priced at $12.37, while INGN trades at $6.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IART currently has a P/E ratio of -32.55, whereas INGN's P/E ratio is -5.70. In terms of profitability, IART's ROE is -0.03%, compared to INGN's ROE of -0.15%. Regarding short-term risk, IART is more volatile compared to INGN. This indicates potentially higher risk in terms of short-term price fluctuations for IART.Check INGN's competition here
IART vs TLSI Comparison July 2025
IART plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IART stands at 961.3M. In comparison, TLSI has a market cap of 168.2M. Regarding current trading prices, IART is priced at $12.37, while TLSI trades at $4.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IART currently has a P/E ratio of -32.55, whereas TLSI's P/E ratio is -4.03. In terms of profitability, IART's ROE is -0.03%, compared to TLSI's ROE of +1.04%. Regarding short-term risk, IART is less volatile compared to TLSI. This indicates potentially lower risk in terms of short-term price fluctuations for IART.Check TLSI's competition here
IART vs PROF Comparison July 2025
IART plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IART stands at 961.3M. In comparison, PROF has a market cap of 166.9M. Regarding current trading prices, IART is priced at $12.37, while PROF trades at $5.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IART currently has a P/E ratio of -32.55, whereas PROF's P/E ratio is -4.59. In terms of profitability, IART's ROE is -0.03%, compared to PROF's ROE of -0.70%. Regarding short-term risk, IART is less volatile compared to PROF. This indicates potentially lower risk in terms of short-term price fluctuations for IART.Check PROF's competition here
IART vs RPID Comparison July 2025
IART plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IART stands at 961.3M. In comparison, RPID has a market cap of 165.7M. Regarding current trading prices, IART is priced at $12.37, while RPID trades at $3.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IART currently has a P/E ratio of -32.55, whereas RPID's P/E ratio is -3.67. In terms of profitability, IART's ROE is -0.03%, compared to RPID's ROE of -0.56%. Regarding short-term risk, IART is less volatile compared to RPID. This indicates potentially lower risk in terms of short-term price fluctuations for IART.Check RPID's competition here
IART vs LNSR Comparison July 2025
IART plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IART stands at 961.3M. In comparison, LNSR has a market cap of 157.9M. Regarding current trading prices, IART is priced at $12.37, while LNSR trades at $13.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IART currently has a P/E ratio of -32.55, whereas LNSR's P/E ratio is -2.73. In terms of profitability, IART's ROE is -0.03%, compared to LNSR's ROE of -5.28%. Regarding short-term risk, IART is more volatile compared to LNSR. This indicates potentially higher risk in terms of short-term price fluctuations for IART.Check LNSR's competition here
IART vs ELMD Comparison July 2025
IART plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IART stands at 961.3M. In comparison, ELMD has a market cap of 156.3M. Regarding current trading prices, IART is priced at $12.37, while ELMD trades at $18.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IART currently has a P/E ratio of -32.55, whereas ELMD's P/E ratio is 23.59. In terms of profitability, IART's ROE is -0.03%, compared to ELMD's ROE of +0.17%. Regarding short-term risk, IART is more volatile compared to ELMD. This indicates potentially higher risk in terms of short-term price fluctuations for IART.Check ELMD's competition here
IART vs RCEL Comparison July 2025
IART plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IART stands at 961.3M. In comparison, RCEL has a market cap of 141.7M. Regarding current trading prices, IART is priced at $12.37, while RCEL trades at $5.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IART currently has a P/E ratio of -32.55, whereas RCEL's P/E ratio is -2.45. In terms of profitability, IART's ROE is -0.03%, compared to RCEL's ROE of -3.38%. Regarding short-term risk, IART is less volatile compared to RCEL. This indicates potentially lower risk in terms of short-term price fluctuations for IART.Check RCEL's competition here
IART vs BSGM Comparison July 2025
IART plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IART stands at 961.3M. In comparison, BSGM has a market cap of 141.6M. Regarding current trading prices, IART is priced at $12.37, while BSGM trades at $4.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IART currently has a P/E ratio of -32.55, whereas BSGM's P/E ratio is -8.53. In terms of profitability, IART's ROE is -0.03%, compared to BSGM's ROE of -35.30%. Regarding short-term risk, IART is less volatile compared to BSGM. This indicates potentially lower risk in terms of short-term price fluctuations for IART.Check BSGM's competition here
IART vs OWLT Comparison July 2025
IART plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IART stands at 961.3M. In comparison, OWLT has a market cap of 127.7M. Regarding current trading prices, IART is priced at $12.37, while OWLT trades at $7.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IART currently has a P/E ratio of -32.55, whereas OWLT's P/E ratio is -4.80. In terms of profitability, IART's ROE is -0.03%, compared to OWLT's ROE of +1.25%. Regarding short-term risk, IART is less volatile compared to OWLT. This indicates potentially lower risk in terms of short-term price fluctuations for IART.Check OWLT's competition here
IART vs LUNG Comparison July 2025
IART plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IART stands at 961.3M. In comparison, LUNG has a market cap of 126.8M. Regarding current trading prices, IART is priced at $12.37, while LUNG trades at $3.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IART currently has a P/E ratio of -32.55, whereas LUNG's P/E ratio is -2.19. In terms of profitability, IART's ROE is -0.03%, compared to LUNG's ROE of -0.64%. Regarding short-term risk, IART is less volatile compared to LUNG. This indicates potentially lower risk in terms of short-term price fluctuations for IART.Check LUNG's competition here
IART vs AVR Comparison July 2025
IART plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IART stands at 961.3M. In comparison, AVR has a market cap of 124.2M. Regarding current trading prices, IART is priced at $12.37, while AVR trades at $3.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IART currently has a P/E ratio of -32.55, whereas AVR's P/E ratio is -0.96. In terms of profitability, IART's ROE is -0.03%, compared to AVR's ROE of -2.92%. Regarding short-term risk, IART is less volatile compared to AVR. This indicates potentially lower risk in terms of short-term price fluctuations for IART.Check AVR's competition here
IART vs ANIK Comparison July 2025
IART plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IART stands at 961.3M. In comparison, ANIK has a market cap of 116.2M. Regarding current trading prices, IART is priced at $12.37, while ANIK trades at $8.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IART currently has a P/E ratio of -32.55, whereas ANIK's P/E ratio is -10.80. In terms of profitability, IART's ROE is -0.03%, compared to ANIK's ROE of -0.35%. Regarding short-term risk, IART is less volatile compared to ANIK. This indicates potentially lower risk in terms of short-term price fluctuations for IART.Check ANIK's competition here
IART vs LUCD Comparison July 2025
IART plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IART stands at 961.3M. In comparison, LUCD has a market cap of 109.3M. Regarding current trading prices, IART is priced at $12.37, while LUCD trades at $1.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IART currently has a P/E ratio of -32.55, whereas LUCD's P/E ratio is -0.86. In terms of profitability, IART's ROE is -0.03%, compared to LUCD's ROE of +26.96%. Regarding short-term risk, IART is less volatile compared to LUCD. This indicates potentially lower risk in terms of short-term price fluctuations for IART.Check LUCD's competition here
IART vs ICAD Comparison July 2025
IART plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IART stands at 961.3M. In comparison, ICAD has a market cap of 106.3M. Regarding current trading prices, IART is priced at $12.37, while ICAD trades at $3.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IART currently has a P/E ratio of -32.55, whereas ICAD's P/E ratio is -20.37. In terms of profitability, IART's ROE is -0.03%, compared to ICAD's ROE of -0.17%. Regarding short-term risk, IART is more volatile compared to ICAD. This indicates potentially higher risk in terms of short-term price fluctuations for IART.Check ICAD's competition here
IART vs HJLI Comparison July 2025
IART plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IART stands at 961.3M. In comparison, HJLI has a market cap of 98.3M. Regarding current trading prices, IART is priced at $12.37, while HJLI trades at $10.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IART currently has a P/E ratio of -32.55, whereas HJLI's P/E ratio is N/A. In terms of profitability, IART's ROE is -0.03%, compared to HJLI's ROE of -0.51%. Regarding short-term risk, IART is more volatile compared to HJLI. This indicates potentially higher risk in terms of short-term price fluctuations for IART.Check HJLI's competition here
IART vs FONR Comparison July 2025
IART plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IART stands at 961.3M. In comparison, FONR has a market cap of 97.8M. Regarding current trading prices, IART is priced at $12.37, while FONR trades at $15.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IART currently has a P/E ratio of -32.55, whereas FONR's P/E ratio is 12.62. In terms of profitability, IART's ROE is -0.03%, compared to FONR's ROE of +0.09%. Regarding short-term risk, IART is more volatile compared to FONR. This indicates potentially higher risk in terms of short-term price fluctuations for IART.Check FONR's competition here